Singapore Pemetrexed Market Size & Outlook, 2025-2033


Singapore Pemetrexed Market Insights

  • As highlighted in Reed Intelligence analysis, the Singapore Pemetrexed Market, worth USD 9.13 Million in 2024, is forecasted to achieve USD 10.09 Million by 2033.
  • The Singapore market is anticipated to grow at a CAGR of 1.13% during the period 2026–2033.
  • By 2024, Malignant Pleural Mesothelioma represented the largest share of the By Application market size.
  • Non-Squamous NSCLC is expected to remain the key growth driver within By Application, registering the fastest CAGR during the forecast period.

Other Key Findings


  • In 2024, Singapore represented 0.39% of the overall global Pemetrexed Market size.
  • United States is projected to lead the global Pemetrexed Market size by 2033.
  • Across Asia Pacific, China is anticipated to hold the dominant position in market size by 2033.
  • India is forecasted to expand at the fastest pace in Asia Pacific, attaining USD 94.95 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 9.13 Million
Market Size In 2033 USD 10.09 Million
Largest segment Malignant Pleural Mesothelioma
Units Revenue in USD Million
CAGR 1.13% (2025-2033)
Segmnetation Covered
By Application
  1. Malignant Pleural Mesothelioma
  2. Non-Squamous NSCLC
By End-User
  1. Hospitals
  2. Oncology Centers
  3. Online Pharmacies
  4. Offline Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends